Do ApoB-containing lipoproteins cause atherosclerosis by penetrating and being retained in the arterial wall?

Atherosclerosis is fundamentally characterized as a lipid-driven inflammatory disease. Current scientific consensus establishes that the retention of Apolipoprotein B (ApoB)-containing lipoproteins within the arterial wall is the primary and essential initiating event in the development of atherosclerotic plaques.

Clinical and Effectiveness Evidence

Large-scale genetic and clinical studies have confirmed the causal role of ApoB particles in cardiovascular disease.

• ApoB as a Superior Predictor: Evidence from major cohorts like the UK Biobank and the CARDIA study indicates that the total concentration of ApoB-containing particles is a more accurate predictor of cardiovascular risk than LDL-cholesterol (LDL-C) alone. This is because every atherogenic particle—including LDL, VLDL, and intermediate-density lipoproteins—contains exactly one molecule of ApoB.
• Log-Linear Risk Relationship: Meta-analyses involving over 200,000 participants demonstrate a consistent log-linear relationship between cumulative exposure to ApoB and the risk of atherosclerotic events. For every 10 mg/dL reduction in ApoB, there is a corresponding decrease of approximately 10% in major cardiovascular events.
• Genetic Confirmation: Mendelian randomization studies show that individuals with genetic variants leading to naturally lower lifetime ApoB levels have significantly lower rates of heart disease, reinforcing that the relationship is causal rather than merely associative.

Mechanistic Explanations

The progression from circulating lipids to a physical plaque involves a specific sequence of biological events known as the "response-to-retention" model.

• Transcytosis and Penetration: ApoB-containing lipoproteins enter the arterial intima primarily through receptor-mediated transcytosis. Receptors such as SR-B1 and ALK1 facilitate the movement of these particles across the endothelial barrier into the subendothelial space.
• The "Chemical Trap": Once inside the arterial wall, the positively charged amino acids on the ApoB-100 molecule bind electrostatically to negatively charged sulfate groups on proteoglycans (like biglycan and versican) in the extracellular matrix. This interaction traps the particles, preventing their exit back into the bloodstream.
• Inflammatory Cascade: Retained lipoproteins undergo modifications, including oxidation and enzymatic cleavage, which transform them into Damage-Associated Molecular Patterns (DAMPs). These modified particles activate the NLRP3 inflammasome within macrophages, leading to the release of pro-inflammatory cytokines such as Interleukin-1 beta (IL-1β).
• Plaque Growth: This chronic inflammatory environment recruits more monocytes, which differentiate into macrophages and engulf the modified lipids to become foam cells. The resulting cycle of lipid accumulation, cellular recruitment, and smooth muscle cell proliferation drives the physical expansion of the plaque.

Bottom line

The evidence strongly supports the claim that ApoB-containing lipoproteins cause atherosclerosis by penetrating and being retained in the arterial wall, which directly triggers the chronic inflammation and cellular accumulation required for plaque growth. This mechanism makes the total ApoB count a critical clinical marker for assessing and managing cardiovascular risk.